Brain delivery Ossianix specializes in delivering biologics across the blood-brain barrier using shark-derived VNAR antibodies, presenting sales opportunities with CNS-focused pharma and biotech companies developing neurodegenerative, neuro-oncology, ALS, or pain therapies.

Strategic partnerships Historical collaborations with Lundbeck and Novo Nordisk highlight a track record of co-development and access to large pharma networks, suggesting a compelling route for new licensing, collaboration, or out-licensing deals.

Early-stage focus As a privately held preclinical company with modest headcount and revenue in the low millions, Ossianix is likely seeking partnering funding, research collaborations, and milestone-driven deals to advance pipeline programs.

Global footprint With headquarters in Philadelphia and research labs in Stevenage, UK, Ossianix offers cross-Atlantic collaboration potential, enabling multinational partnerships and access to diverse regulatory and academic ecosystems.

Specialized tech VNAR antibody platform targeting difficult-to-reach brain targets positions Ossianix to complement therapeutic programs requiring brain delivery, potentially expanding the addressable market for CNS indications and BBB-crossing biologics.